Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
ConditionMeningioma
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-99
SponsorWeill Medical College of Cornell University
About this trial
The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.
Eligibility criteria
Qualifiers
High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent or residual tumor necessitating repeat surgery.
Disqualifiers
Pregnant or breastfeeding
Patients undergoing endoscopic endonasal resection, eyebrow incision surgery, or any surgical procedure in which the neoprobe cannot be employed
Patients with hypersensitivity to somatostatin analogs
Patients with contraindications to conventional MRI
Trial design
Treatments tested in this trial
- Brain Imaging with [Cu64]DOTATATE
- Radio-guided Surgery With Neoprobe Utilization
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Weill Medical College of Cornell University
Lead sponsor
Curium US LLC
Collaborator
Source ClinicalTrials.gov